Arrowhead price target raised to $11 from $5.50 at Piper Jaffray. Piper Jaffray analyst Edward Tenthoff raised his price target on Arrowhead Pharmaceuticals to $11 and kept his Overweight rating after the company’s Q2 results. The analyst notes that after initiating Phase 1 studies of ARO-HBV and ARO-AAT, the company’s interim data is now potentially expected at AASLD in November. Tenthoff models a higher price target on Arrowhead to reflect is added pipeline value.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.